Detalles de la búsqueda
1.
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
Br J Haematol
; 204(1): 151-159, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37690811
2.
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Blood
; 140(17): 1907-1916, 2022 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35789260
3.
Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
Cancer
; 129(2): 255-263, 2023 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36385707
4.
Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
Br J Haematol
; 201(4): 653-662, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36733229
5.
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.
Br J Haematol
; 196(5): 1184-1193, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34951009
6.
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Haematologica
; 107(5): 1153-1162, 2022 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34289655
7.
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma.
Haematologica
; 107(5): 1131-1143, 2022 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34162177
8.
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma.
Hematol Oncol
; 40(5): 864-875, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35850118
9.
CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).
Haematologica
; 106(11): 2918-2926, 2021 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33054126
10.
A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma.
Haematologica
; 106(9): 2405-2416, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32817282
11.
A new frontier for R-CHOP: is two better than one?
Blood
; 142(16): 1331-1332, 2023 10 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37856095
12.
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.
Oncologist
; 24(9): 1246-1252, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30940746
13.
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.
Am J Hematol
; 94(6): 628-634, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30829413
14.
Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.
Haematologica
; 103(8): 1345-1350, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29748444
15.
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ann Hematol
; 97(9): 1619-1626, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29663029
16.
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Lancet Oncol
; 18(8): 1076-1088, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28668386
17.
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
Am J Hematol
; 97(1): E24-E27, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34731510
18.
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma.
Future Oncol
; 12(13): 1553-63, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27089170
19.
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
Blood
; 122(23): 3759-66, 2013 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-24085766
20.
Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma.
Haematologica
; 105(2): e72-e75, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31221781